Read INHALT_Final_Pro_2013.indd text version

7th International Symposium on the Clinical Use of Cellular Products

Final Program

Cellular Therapy 2013

March 14 and 15, 2013, Erlangen, Germany

Universitatsklinikum Erlangen

7th International Symposium on the Clinical Use of Cellular Products

Cellular Therapy 2013

March 14 and 15, 2013 Department of Internal Medicine 5 ­ Hematology/Oncology University of Erlangen-Nuremberg Department of Dermatology University of Erlangen-Nuremberg Department of Hematology/Oncology University of Regensburg

Under the Patronage of

Supported by

Deutsche Forschungsgemeinschaft

Deutsche Forschungsgemeinschaft

Cooperating Institutions

BayImmuNet Bavarian Immunotherapy Network

SFB 643 Strategies of Cellular Immune Intervention

GK1660 Adaptive Immunity

MICE Medical Immunology Campus Erlangen

Comprehensive Cancer Center Erlangen Europäische Metropolregion Nürnberg

Welcome Address

Dear Colleagues. On behalf of the organizing committee we would like to welcome you to the 7th International Cellular Therapy Symposium in Erlangen. The Cellular Therapy Symposium is co-organized by the Universities of Erlangen-Nuremberg (A. Mackensen; G. Schuler) and Regensburg (R. Andreesen). Cellular therapy is both, a standard treatment modality with curative potential in the form of hematopoietic stem cell transplantation and, when immune effector, suppressor or antigen presenting cells are used, a fascinating, rapidly developing new approach for the treatment of cancer, infectious diseases, graft-versus host disease, and autoimmune diseases. Over the past years the meeting has evolved to a widely respected event, attracting experts from all over the world to discuss recent topics of the field in a pleasant environment. The upcoming meeting 2013 will focus on immune effector cells, suppressor cells, antigen presenting cells, genetically-modified cellular therapy, the clinical application of virus-specific T cells, vaccination, and imaging of cell-based therapies. Thank you for joining us here in Erlangen and for your contributions to create a stimulating environment and a successful meeting. Yours sincerely

Andreas Mackensen

General Information

Organizer: Prof. Dr. A. Mackensen Department of Internal Medicine 5 ­ Hematology and Oncology Ulmenweg 18 D-91054 Erlangen, Germany Phone: +49-9131-85 35954 Fax: +49-9131-85 35958 E-mail: [email protected] [email protected] Conference Site Hörsaalgebäude Universitätsklinikum Erlangen Ulmenweg 18 91054 Erlangen, Germany Coffee Break and Lunch During session breaks, coffee and cake will be served to participants wearing their badges. The coffee break will take place in the lobby. Lunch on March 14 and brunch on March 15 is included in the registration fee and will also take place in the lobby. Social Event A social evening with dinner and live music will be organized at the restaurant Schloss Atzelsberg, Marloffstein-Atzelsberg, on Thursday, March 14 at 19.30 h (7.30 pm).

General Information

Opening hours of the conference office Wednesday, March 13, 2013 15.00 ­ 17.00 h Thursday, March 14, 2013 07.30 ­ 18.30 h Friday, March 15, 2013 08.00 ­ 16.00 h

During the conference you can contact us at: Phone: +49-91 31 - 85 43100 Fax: +49-91 31 - 85 35758 Mobile phone: +49-173 - 8611442

Registration: Participants can register onsite (cash only) Full Registration: Students: Members of the University of Erlangen & Regensburg: 300 175 150

The registration fee covers conference volume, coffee breaks, lunch, brunch and social event.

Tourist Information Erlangen Erlanger Tourismus und Marketing Verein e.V. Carree am Rathausplatz Rathausplatz 3 91052 Erlangen Phone: +49 (0)91 31 89 51-11 Fax: +49 (0)91 31 89 51-51 Mail: [email protected]

Organizer:

Andreas Mackensen, Erlangen Gerold Schuler, Erlangen Reinhard Andreesen, Regensburg

Scientific Committee:

Andreas Mackensen, Erlangen Wolfgang Herr, Mainz Evelyn Ullrich, Erlangen Matthias Theobald, Mainz Wolfgang Uckert, Berlin Armin Gerbitz, Erlangen Matthias Edinger, Regensburg Petra Hoffmann, Regensburg Dimitrios Mougiakakos, Erlangen Dolores Schendel, Munich Gerold Schuler, Erlangen Reinhard Andreesen, Regensburg Robert Zeiser, Freiburg

Congress Secretary:

Armin Gerbitz Department of Internal Medicine 5 ­ Hematology and Oncology Ulmenweg 18 D-91054 Erlangen, Germany Phone: +49-9131-85 35954 Fax: +49-9131-85 35958 Mail: [email protected]

Thursday March 14, 2013

08.30 h

Opening Andreas Mackensen

Director of the Department of Internal Medicine 5 ­ Hematology and Oncology University of Erlangen-Nuremberg

Welcome Addresses Christoph Korbmacher

Vice President of the University of Erlangen-Nuremberg

Jürgen Schüttler

Dean of the Faculty of Medicine, University of Erlangen-Nuremberg

Thursday March 14, 2013

Key Note Lecture

8.45 h - 9.25 h

Session I Genetically-modified Cellular Therapy

9.25 h - 11.10 h

Chairmen:

Matthias Theobald (Mainz) Wolfgang Uckert (Berlin)

Thursday March 14, 2013

Key Note Lecture

01 08.45­09.25 Preventing cancer relapse by cellular immunotherapy H. Schreiber, Chicago

Session I

02 09.25­09.50 Adoptive transfer of chimeric antigen receptor-modified T cells C. June, Philadelphia CARs transform to TRUCKs: T cells with inducible IL-12 produce an improved anti-cancer attack toward antigen-loss tumor cell variants H. Abken, Cologne Genetic engineering of T-cell specificity R. Willemsen, Rotterdam RNAi-assisted TCR protein replacement reduces severe autoimmune reactions caused by mixed TCR dimers M. Bunse, Berlin Working against the clock: Affinity thresholds in tolerance and autoimmunity E. Palmer, Basel Electroporation of TCR-encoding mRNA to reprogram bulk CD8+ and / T lymphocytes with a specificity for adenovirus N. Schaft, Erlangen Lunch and Poster Discussion Authors are requested to be present at their poster

03

09.50­10.00

04

10.00­10.25

05

10.25­10.35

06

10.35­11.00

07

11.00­11.10

11.20 - 13.30

Thursday March 14, 2013

Session II Immune Effector Cells (T Cells, NK Cells)

13.30 h - 15.25 h

Chairmen:

Rolf Kiessling (Stockholm) Wolfgang Herr (Mainz)

Thursday March 14, 2013

08 13.30 - 13.55 T-cell exhaustion in cancer: a state of partial T cell attenuation, not necessarily compromising immunotherapy D. Speiser, Lausanne Novel strategies to increase the efficacy and reduce toxicity of adoptive T cell therapy with TILs R. Andersen, Copenhagen Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity in cancer patients S. Hodi, Boston Long term persistence of EBV specific T cells after adoptive transfer monitored by next generation sequencing on a single cell level J. Ritter, Berlin Interleukin-22-producing innate lymphoid cells protect intestinal epithelial stem cells against tumor transformation A. Diefenbach, Freiburg Donor T cells specific for hematopoietic-restricted minor histocompatibility antigens are induced in patients with combined GvL and GvHD M. Pont, Leiden Acute myeloid leukemia (AML)-reactive CD4+ T-cell clones isolated from 10/10 HLA match donors recognize HLA-DP mismatch antigens and eliminate leukemia blasts in NSG mice in vivo Y. Eichinger, Mainz Coffee break

09

13.55 - 14.05

10

14.05 - 14.30

11

14.30 - 14.40

12

14.40 - 15.05

13

15.05 - 15.15

14

15.15 - 15.25

15.25 - 16.00

Thursday March 14, 2013

Session III Imaging of Cell-based Therapies

16.00 h - 17.45 h

Chairmen:

Matthias Gunzer (Essen) Armin Gerbitz (Erlangen)

Thursday March 14, 2013

15 16.00 - 16.25 Long-range communication between tumors and the immune system M. Pittet, Boston Tracking of adoptive Treg therapy in transplantation: a pre-clinical model E. Sharif-Paghaleh, London Mapping complex immune processes after allogeneic hematopoietic cell transplantation A.Beilhack, Würzburg PET based imaging of neoangiogenesis in the intestines of mice developing GvHD F. Leonhardt, Freiburg The physiology of stem cells and neutrophils in the bone marrow and at peripheral effector sites M. Gunzer, Essen Preclinical imaging of innate immune responses R. Zeiser, Freiburg Social Event: Schloss Atzelsberg, Marloffstein-Atzelsberg

16

16.25 - 16.35

17

16.35 - 17.00

18

17.00 - 17.10

19

17.10 - 17.35

20

17.35 - 17.45

19.30

Friday March 15, 2013

Session IV Suppressor Cells (Treg Cells, Mesenchymal Stem Cells)

09.00 h ­ 10.55 h

Chairmen:

Li Zhang (Toronto) Matthias Edinger (Regensburg)

Friday March 15, 2013

21 09.00 - 09.25 Multipotent mesenchymal stem cells in allogeneic stem cell transplantation K. le Blanc, Stockholm Treatment of steroid resistant grade II to IV acute GVHD by infusion of mesenchymal stroma cells expanded with human plasma and platelet lysate - a phase I/II study: clinical results and comprehensive immunological analysis J. Kuball, Utrecht Stability and adaptability of Foxp3+ regulatory T cells S. Hori, Kanagawa Direct PD-1-mediated suppression of autoreactive B cells by regulatory T cells J. Gotot, Bonn Modulation of Treg in vivo with low dose IL-2 J. Ritz, Boston Regulatory T cells preserve anti-viral immunity while preventing lethal graft-versus-host disease M. Seefried, Erlangen Therapeutic TNFR2-activation in vivo prior to allogeneic hematopoietic stem cell transplantation protects from lethal acute GVHD by selectively expanding host regulatory T cells while maintaining GVL effects M. Chopra, Würzburg Brunch

22

09.25 - 09.35

23

09.35 - 10.00

24

10.00 - 10.10

25

10.10 - 10.35

26

10.35 - 10.45

27

10.45 - 10.55

11.00 - 12.00

Friday March 15, 2013

Session V Antigen Presenting Cells & Vaccination

12.00 h - 13.55 h

Chairmen:

Dolores Schendel (München) Alexander Steinkasserer (Erlangen)

Friday March 15, 2013

28 12.00 - 12.25 Imaging T-cell - dendritic cell dynamics in vivo: mechanism of Treg-mediated suppression of CD8+ T-cell response S. Amigorena, Paris Src-kinase inhibitors sensitize human dendritic cells to Toll-like-receptor-induced IL12 synthesis M. Wölfl, Würzburg Therapeutic DC vaccines targeting cancer stem cells in glioblastoma - clinical experiences and future perspectives G. Kvalheim, Oslo Phase I/II clinical trials of dendritic cell-based immunotherapy in patients with the biochemical relapse of the prostate cancer R. Spisek, Prague Dendritic cells and myeloma - new opportunities for risk-adapted immunoprevention M. Dhodapkar, Yale Vitamin D triggers killing of B-cell lymphoma cells by macrophages H. Bruns, Erlangen Transcriptional targeting of mature dendritic cells by the newly characterized human CD83 promoter ­ prospects for new in vivo DC-vaccination strategies I. Knippertz, Erlangen Coffee Break

29

12.25 - 12.35

30

12.35 - 13.00

31

13.00 - 13.10

32

13.10 - 13.35

33

13.35 - 13.45

34

13.45 - 13.55

14.00 - 14.30

Friday March 15, 2013

Session VI Virus-specific T cells ­ Clinical Application

14.30 h - 15.45 h

Chairmen:

Hermann Einsele (Würzburg)

Friday March 15, 2013

35 14.30 - 14.55 CMV:constraining the enemy within K. Peggs, London Cell therapy for viral infections developing after stem cell transplantation in paediatric patients P. Comoli, Pavia Immunotherapy targeting viral infection and viral cancers H. Heslop, Houston Summary A. Mackensen

36

14.55 - 15.20

37

15.20 - 15.45

15.45

Sponsored by an unrestricted educational grant from Cell Medica Ltd.

Thursday March 14, 2013

Poster Session

11.10 h - 13.30 h

Poster Session A Immune Effector Cells (T Cells, NK Cells, NK T Cells)

A1 Activated NK cells are more potent immunotherapy effectors against glioblastoma compared to LAK cells mediated by activating KIR-ligand interactions in vitro A. Gras Navarro, Bergen Adoptively transferred antigen specific T cells exhibit an exhausted phenotype after total body irradiation in a murine model of gastric cancer-derived tumor Y. Zeng, München Antifungal activity of human natural killer cells S. Schmidt, Frankfurt B-cell lymphomas with distinct defects in apoptosis and senescence are targets for antigen specific T-cells C. Fahrenwald, Erlangen Basophils as regulators of CD4 T cells in graft versus host disease F. Hermann, Regensburg Basophils control T cell Responses and limit Disease Activity in Experimental Murine Colitis M. Rodriguez Gomez, Ontario Batf-/- T cells are not pathogenic in an acute GvHD mouse m J. Rothamer, Erlangen Batf-dependent Th17 cells are critical mediators of the inflammationassociated coloncarcinogenesis E. Punkenburg, Erlangen CD11b+ NK cells are the main effector NK cell subpopulation that interferes with GVHD E. Ullrich, Frankfurt CD4+ T-helper cells, DC, and CD8+ T cells must concurrently interact to elicit an effective secondary CTL expansion S. Böhm, Erlangen

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

Cell surface delivery of TRAIL augments the tumoricidal activity of T-cells E. Bremer, Groningen Characterization of the biological function of CD83 using tissue-specific knock-out mice L. Krzyzak, Erlangen Characterization of tumor associated b cells in colorectal cancer H. Schlößer, Köln Efficient Generation of Human Natural Killer Cells by Viral Tr A. Ensser, Erlangen Elevated CD3+ and CD8+ tumor­infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor and peripheral microenvironment J. Kmiecik, Bergen Ex vivo expanded human DNT cells as a potential novel immunotherapy for AML L. Zhang, Toronto Exploring leukemia- and virus-reactive CD8+ T lymphocytes with stem-cell-like and central memory properties for effective immunotherapy using humanized mice Y. Xu, Mainz Graft-versus-host disease ­ The destroyer of the B cell compartment? K. Doser, Regensburg HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A S. Bolduan, Erlangen HLA-C-restricted T cells selectively recognize human cytomegalovirus in spite of viral immunoevasion A.Moosmann, München Identical epitope-specific cellular immunity in autoimmune and malignant thyroid diseases M. Ehlers, Düsseldorf Immunomonitoring of patients after double cord blood and MHC matched stem cell transplantation by using EBV and CMV specific MHC multimers M. Wurdack, Erlangen

A12

A13 A14 A15

A16 A17

A18 A19

A20

A21

A22

A23

Improving the therapeutic potential of adoptively transferred human NK cells in a melanoma xenograft model M. Miller, Heidelberg Induction of killer immunoglobulin-like receptor (KIR) expression on NK cells potentiates in vivo alloreactivity against pediatric B cell precursor leukemia in a NOD/SCID/IL2Rnull xenotransplantation model M. Andre, Mainz Investigation and inhibition of tumor immune escape from NKG2D-dependent NK cell cytotoxicity A.Groth, Mainz NK cell subsets isolated from human thymus differ from peripheral blood NK cells in their phenotype and their cytotoxic and cytokine secreting capabilities S. Krieg, Erlangen Preferential lysis of antigen double-positive leukemic cells mediated by dualtargeting triplebodies and NK effector cells G. Fey, Erlangen Primary and metastatic uveal melanoma cell lines express MelanA and gp100 that can be used as target antigens for transfection of mature dendritic cells S. Britting, Erlangen Pseudo-exhaustion of CD8+ T cells in AML K. Emmerig, München qPCR gene expression profiles in peripheral blood mononuclear cells of breast cancer patients I. Vancurov, Prag Rapid method to screen for CMV, EBV and AdV specific T cells in multiple samples M. Assenmacher, Bergisch-Gladbach Suppression of human adaptive immunity by the tumor metabolite 5`-deoxy-5`methylthioadenosine F. Henrich, Erlangen T-cell targeting of huCD19 as B-cell specific antigen in mice A.Maurberger, Erlangen Treg cell-independent protection from acute graft versus host disease after polyclonal stimulation of allogeneic T cells in vitro N. Beyersdorf, Würzburg

A24

A25

A26

A27

A28

A29 A30

A31 A32

A33 A34

Poster Session B Suppressor Cells (Treg Cells, Mesenchymal Stem Cells, Myeloid Suppressor Cells)

B1 Adoptive Transfer of Mouse Regulatory Macrophages Prolongs Cardiac Allograft Survival via IFN--induced iNOS Expression P. Riquelme, Regensburg Characterization of immunoregulatory human TCR+ CD4- CD8- doublenegative T cells A. Allgäuer, Erlangen Characterization of Immunosuppressive Cells in Peripheral Blood from Prostate Cancer Patients M. Idorn, Herlev Depletion of CCR2+ myeloid cells results in reduced tumor growth in B16 mouse melanoma K. Singer, Regensburg Development of a Reliable Manufacturing Process for Clinical Production of M regs C. Florian, Regensburg Expanded cryopreserved MSC as a optimal source for GVDH treatment M. Holubov, Pilsen Human regulatory macrophages induce a functionally suppressive phenotype in allogeneic T cells L. Walter, Regensburg Impact of donor-derived CD4+CD25+ regulatory T cells on graft-versus-host disease of the gastrointestinal tract C. Riegel, Regensburg Induction of donor-specific tolerance in organ transplantation using in vitro-generated immunosuppressive myeloid blood cells C. Kleist, Heidelberg

B2

B3

B4

B5

B6

B7

B8

B9

B10

Physiological concentrations of 25-hydroxyvitamin D3 induce regulatory T cells (Treg) K. Peter, Regensburg Reconstitution of GPI-anchor negative Treg is associated with higher risk of acute GVHD after Alemtuzumab-based T-cell depletion L. Schäfer, Mainz Trafficking and Immunological Effects of Human Regulatory Macrophages in Renal Transplant Recipients J. Hutchinson, Regensburg Tumor Infiltrating B cells in Primary Cutaneous T-cell Lymphomas Correlate with Disease Progression and Represent a Potential Therapeutic Target within the Tumor Microenvironment M. von Bergwelt-Baildon, Köln

B11

B12

B13

Poster Session C Antigen Presenting Cells & Vaccination

C1 6-color confocal immunofluorescence microscopy of DCs in human tissue N. Eissing, Erlangen A DC-based therapeutic vaccine for AML patients: preclinical evaluation of a new generation of DCs expressing the leukemia-associated antigens WT1 and PRAME C. Geiger, München Analysis of CD19+/CD38+/CD27high plasma blasts in allogeneic stem cell transplant patients after routinely performed re-vaccination J. Winkler, Erlangen Analysis of Dendritic Cells in human lymphoid organs G. Heidkamp, Erlangen Antigen targeting to Fc receptors expressed on DCs - but not other cell types induces efficient CD4 and CD8 T cell responses in vivo C. Lehmann, Erlangen Combinatorial approaches of chemotherapy with immunotherapy for melanoma influence of chemotherapeutic drugs on the functions of immune cells S. Gross, Erlangen Dasatinib enhances migration of monocyte-derived dendritic cells and hampers their cytokine secretion without diminishing their ability to induce virus-specific CD8+ T cell responses T. Nerreter, Würzburg Establishment of predictive biomarkers for dendritic cell vaccination of melanoma patients L. Heinzerling, Erlangen DM-sensitive antigens are appropriate targets for CD4+ T-cell mediated Graftversus-Leukemia reactivity A. Kremer, Erlangen Do combinatory treatments with ionizing irradiation, temozolomide and valproic acid induce immunogenic glioblastoma tumor cells? Y. Rubner, Erlangen

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

From mouse to man: Activation of human APC by the novel adjuvant TDB via the Mincle receptor? J. Ostrop, Erlangen Generation of an autologous whole tumor cell based vaccine by the induction of high immunogenic tumor cell death with high hydrostatic pressure G. Frey, Erlangen Intercellular transfer of natural HLA class II ligands is mediated by full length proteins with abundant cellular expression that are sequestered and secreted into microvesicles A. Kremer, Erlangen Just one position-independent lysine residue can direct MelanA into proteasomal degradation following N-terminal fusion of ubiquitin C. Setz, Erlangen Mature proteins fail to feed into the MHC class I antigenic pool B.Fiebiger, München Modulation of artificial APC mediated immune cell interaction H. Bruns, Erlangen Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the zVAD-fmk results in activation of dendritic cells and macrophages N. Werthmüller, Erlangen Mutated and over-expressed tumor antigens: qualified for cancer immunotherapy? S. Höfflin, Erlangen Mutated BRAF and NRAS proteins as targets in therapeutic melanoma vaccination S. Prommersberger, Erlangen Novel role of CD11c+CD8- DCs in induction of cytotoxic T cell activation A. Baranska, Erlangen On or off? - Manipulation of the two NF-B pathways with constitutively active or dominant negative forms of the activators in dendritic cells I. Pfeiffer, Erlangen RNA electroporation; DC couldn't care less J. Dörrie, Erlangen Targeting dendritic cells with functionalized HES nanocapsules P. Okwieka, Mainz

C12

C13

C14

C15 C16 C17

C18 C19 C20 C21

C22 C23

Poster Session D Genetically-modified Cellular Therapy

D1 A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumor model S. Kobold, München Characterization of HER2-specific cytoxic T-cell responses after in-vitro stimulation E. Bräunlein, München Construction and characterization of an antibody derived trimeric molecule for transduction of PSMA-positive prostate cancer cells A. Schlegel, Erlangen Gene therapy with a high-affinity single-chain p53-specific TCR triggers effective antitumor reactivity without on/off-target autoimmunity in vivo H. Echchannaoui, Mainz Heterogeneity and Cytogenetic Abnormality of Tumor Endothelial Cells in Human Colorectal Carcinoma E. Naschberger, Erlangen HLA-universal platelet infusions prevent platelet refractoriness in a mouse model C. Gras, Hannover Human memory versus naive derived CD8+ T cells do not induce regression of allogeneic human hematopoiesis in NSG mice making them attractive for T-cell receptor RNA therapy in allogeneic transplantation S. Thomas, Mainz NSG-HLA-A2-transgenic mice are suitable tools to evaluate the effector function of human cytomegalovirus-specific T cells in vivo S. Thomas, Mainz Oral gene therapy via histone encoding chitosan-DNA nanoparticles reduces disease related antibody levels in a murine (NZB x NZW)F1 lupus-model K. Goldmann, Erlangen Retargeting T cells to viral glycoproteins for adoptive therapy of human Cytomegalovirus infection J. Proff, Erlangen

D2

D3

D4

D5

D6 D7

D8

D9

D10

D11

T cells engineered to express high but not lower affinity T cell receptors recognize human tumor antigen cross-presented by the stroma and eradicate large tumors M. Leisegang, Berlin T-cell Receptor Transfer for Boosting HIV-1-specific T-cell Immunity in HIV-1-infected Patients C. Mummert, Erlangen T-cells co-transduced with Chimeric Antigen Receptors and Catalase are protected from Reactive Oxygen Species M. Ligtenberg, Stockholm The importance of epitope choice for adoptive T cell therapy A. Textor, Berlin Towards clinical TCR gene therapy: the optimal TCR transgene cassette T. Straetemans, Utrecht

D12

D13

D14 D15

Poster Session E Cellular Therapy: Clinical Application

E1 A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy S. Grassmann, München Benefit of primary bone marrow-derived endothelial cells in tissue regeneration approaches A. Brandl, Erlangen Comparison of the content of regulatory CD3+CD4+CD25+ T-cells in Umbilical Cord Blood (UCB) compared to leukapheresis products (LP) collected from adults E. Strasser, Aachen Depletion of naive T cells using clinical grade magnetic CD45RA beads reduces alloreactivity and preserves immune responses to common pathogens D. Teschner, Mainz Generating tumor-specific, MHC-independent T cells by RNA electroporation at a clinically feasible scale C.Krug, Erlangen Generation of peptide stimulated CMV and EBV specific T cells derived from G-CSF mobilized and not mobilized allogeneic donors for adoptive transfer after hematopoetic stem cell transplantation R. Gary, Erlangen Generation of tumor-antigen specific T cells under highly controlled environmental conditions by utilization of a novel cGMP compliant cell culture reactor S. Schaffer, Erlangen Targeted Therapy with Brentuximab Vedotin combined with Donor Lymphocyte Infusions induce Sustained Clinical Remissions and Tumor Specific Immunity in Relapses of Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation M. von Bergwelt-Baildon, Köln The reversible Streptamer technology: preserving full biologic function of isolated target cells S. Dreher. München Time-of-flight magnetic flow cytometry in whole blood with integrated sample preparation M. Helou, Erlangen

E2

E3

E4

E5

E6

E7

E8

E9

E10

Poster Session F Imaging of Cell-based Therapies

F1 Combining multiparametric MRI & support vector machine based post processing for the localization of cells in-vivo C. Weis, Erlangen Development of clinically implementable imaging strategies for tracking T cell receptor-transgenic T cells S. Mall, München

F2

Invited Speakers

Amigorena, Sebastian Institut Curie Institut National de la Santé et de la Recherche Médicale U932 F-75245 Paris Cedex 05 France [email protected] Beilhack, Andreas Interdisciplinary Center for Clinical Research (IZKF) Department of Medicine II Würzburg University Clinics, Würzburg Germany [email protected] Comoli, Patrizia Transplant Immunology and Pediatric Hematology Oncology IRCCS Policlinico San Matteo Piazzale Golgi 2 27100 Pavia Italy [email protected] Dhodapkar, Madhav Yale Cancer Center Yale School of Medicine 333 Cedar Street, Box 208021 New Haven, CT 06510 USA [email protected] Diefenbach, Andreas Institut für Med. Mikrobiologie und Hygiene Universitätsklinikum Freiburg Hermann-Herder-Str. 11 79104 Freiburg Germany [email protected] Gunzer, Matthias Institut für Experimentelle Immunologie und Bildgebung Universität Duisburg-Essen Hufelandstrasse 55 45122 Essen Germany [email protected] Heslop, Helen Center for Cell and Gene Therapy Baylor College of Medicine The Methodist Hospital and Texas Children`s Hospital 1102 Bates St, Suite 1640 Houston, TX 77030 USA [email protected] Hodi, F. Stephen Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA, 02215 USA [email protected]

Invited Speakers

Hori, Shohei Research Unit for Immune Homeostasis RIKEN Research Center for Allergy and Immunology 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan [email protected] June, Carl Department of Medicine Perleman School of Medicine at the University of Pennsylvania Philadelphia, PA USA [email protected] Kvalheim, Gunnar Departments of Cellular Therapy Immunology Oncology Biophysics The Norwegian Radiumhospital Oslo University Hospital Oslo Norway [email protected] Le Blanc, Katarina Department of Laboratory Medicine Karolinska Institute 171 77 Stockholm Sweden [email protected] Palmer, Ed Department of Biomedicine University Hospital Basel Hebelstrasse 20 4031 Basel Switzerland [email protected] Peggs, Karl Department of Haematology UCL Cancer Institute, Paul O`Gorman Building University College London, 72 Huntley Street, London WC1E 6BT, UK United Kingdom [email protected] Pittet, Mikael Center for Systems Biology Massachusetts General Hospital and Harvard Medical School 185 Cambridge Street, Room 5228 Boston, MA 02114 USA [email protected] Ritz, Jerome Dana-Farber Cancer Institute Harvard Medical School 450 Brookline Ave. Boston, MA 02215-5450 USA [email protected]

Invited Speakers

Schreiber, Hans Dept. of Pathology; AMB G308, (MC 1089) University of Chicago 5841 South Maryland Avenue Illinois 60637, Chicago USA [email protected] Speiser, Daniel Clinical Tumor Biology & Immunotherapy Group Ludwig Center and Service of Radiation Oncology, Univ. of Lausanne Lausanne Switzerland [email protected] Willemsen, Ralph APO-T B.V., R&D, Leiden The Netherlands [email protected]nl Zeiser, Robert Internal Medicine I Hematology and Oncology University Hospital of Freiburg Hugstetter Straße 55 79106 Freiburg Germany [email protected]

Major Sponsors

Sponsors / Exhibitors Sponsoring this event for purposes of advertising

Alexion Pharma GmbH AMGEN GmbH Astellas Pharma GmbH Bayer Vital GmbH Beckman Coulter GmbH Becton Dickinson GmbH ­ BD Biosciences Bristol-Myers Squibb GmbH & Co. KGaA Celgene GmbH CellGenix GmbH Cell-Medica Ltd. Consarctic GmbH eBioscience GmbH EUFETS GmbH Fresenius Biotech GmbH Janssen-Cilag GmbH Johnson & Johnson MEDICAL GmbH Therakos Medac GmbH Merck SERONO GmbH Miltenyi Biotec GmbH 22.100 Euro 22.100 Euro 22.100 Euro 22.100 Euro 23.000 Euro 23.000 Euro 22.100 Euro 22.100 Euro 10.000 Euro 22.100 Euro 22.085 Euro 22.100 Euro 22.100 Euro 22.100 Euro

Sponsors / Exhibitors Sponsoring this event for purposes of advertising

MSD Sharp & Dohme GmbH Novartis Pharma GmbH PeproTech GmbH Pfizer Pharma GmbH Roche Pharma AG Sepropharm GmbH Spectrum Pharmaceuticals GmbH Takeda Pharma GmbH 22.750 Euro 22.100 Euro 22.100 Euro 22.100 Euro 22.100 Euro 20.000 Euro

Map

Parking Address: Schwabachanlage 14 Conference site and lunch Poster Session

Railway Station

Notes

Notes

Information

INHALT_Final_Pro_2013.indd

44 pages

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

1335079